One of the limitations of cancer therapy is off-target activity, which often has devastating effects on patients’ life quality. A novel strategy pursued by Cybrexa Therapeutics uses treatments specifically targeting solid tumors by taking advantage of one of their universal biomarkers – acidity. By using cell-penetrating peptides bearing an anticancer cargo load, their platform brings the treatment directly inside tumors, leaving healthy cells alone and minimizing bystander killings.
Create your
podcast in
minutes
It is Free